13F-HR: Sanofi Discloses Q3 2025 Equity Portfolio Holdings

Sanofi's latest 13F filing reveals its public equity holdings as of September 30, 2025, totaling over $260 million across nine biotechnology and pharmaceutical companies.

Summary

• Sanofi, the institutional investment manager, filed its Form 13F-HR for the quarter ended September 30, 2025.
• The report details holdings in 9 different public equity securities.
• The total market value of these reported holdings is $260,361,143.
• Key holdings include MeiraGTx Holdings plc with a value of $100,387,376 (12,197,737 shares), Novavax with $59,653,770 (6,880,481 shares), and Inhibrx Biosciences, Inc. with $38,998,948 (1,157,926 shares).
• Other significant holdings include AnaptysBio ($25,167,099), Immuneering Corp CLASS A COM ($18,959,913), and Omada Health Inc. ($11,605,605).
• Smaller positions include LAVA Therapeutics N.V. ($2,994,350), Eledon ($2,110,798), and Q32 Bio Inc. ($483,284).
• Sanofi maintains sole voting authority over all reported shares.

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of an institutional investor's equity holdings, providing factual data without inherent positive or negative sentiment regarding Sanofi's operational performance or future prospects.

Positives

• The filing provides transparency into Sanofi's public equity investment strategy for the reported quarter.
• The portfolio demonstrates diversification across nine distinct biotechnology and pharmaceutical companies.

Negatives

• The information reflects holdings as of September 30, 2025, and may not represent Sanofi's current portfolio composition.
• The filing does not provide insights into the rationale behind specific investment decisions or future investment plans.

Risks

• This filing is a disclosure of past holdings and does not contain specific risk factors related to Sanofi's operations or the held securities.

Future Outlook

This Form 13F-HR filing is a historical disclosure of past equity holdings and does not contain any forward-looking statements or guidance from Sanofi regarding its future investment strategy or market outlook.

Industry Context

Sanofi, a global pharmaceutical company, has disclosed its public equity holdings, which are predominantly concentrated in the biotechnology and pharmaceutical sectors. This aligns with its core business and suggests a strategic focus on companies within its industry ecosystem, potentially for innovation scouting or strategic partnerships.

Comparison to Industry Standards

• The filing of Form 13F-HR is a standard regulatory requirement for institutional investment managers with investment discretion over $100 million or more in Section 13(f) securities, ensuring transparency in their public equity holdings.
• Sanofi's portfolio composition, heavily weighted towards biotech and pharma, is consistent with what might be expected from a large pharmaceutical company's strategic investment arm, often seeking exposure to emerging technologies or therapeutic areas.

Stakeholder Impact

• Provides transparency to Sanofi's shareholders and the broader market regarding its public equity investment activities.
• Offers insights to investors tracking institutional money flows into the listed biotechnology and pharmaceutical companies.

Key Dates

Keywords

Sanofi, 13F, institutional holdings, equity portfolio, investment management, Q3 2025, biotechnology, pharmaceuticals, Inhibrx Biosciences, LAVA Therapeutics, MeiraGTx Holdings, Novavax, AnaptysBio, Immuneering Corp, Eledon, Q32 Bio, Omada Health